Tiziana Life Sciences Ltd
Research Tiziana Life Sciences Ltd (TLSA) on Bullrun: market cap USD 151.44M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTLSA
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 151.44M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 18.43M
- Free cash flow-USD 12.87M
Valuation Snapshot
latest market cap is USD 151.44M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 18.43M | -USD 12.87M | n/a | -0.16 | USD 4.01M | USD 456.00K | USD 52.00K |
| FY2024 | USD 0 | -USD 11.86M | -USD 1.55M | n/a | -0.11 | USD 3.72M | USD 106.00K | USD 3.94M |
| FY2023 | USD 0 | -USD 17.69M | -USD 15.70M | n/a | -0.17 | USD 1.18M | USD 247.00K | USD 5.54M |
| FY2022 | USD 0 | -USD 15.40M | -USD 19.62M | n/a | -0.15 | USD 18.12M | USD 365.00K | USD 19.57M |
| FY2021 | USD 0 | -USD 23.42M | -USD 21.78M | n/a | -0.24 | USD 42.19M | USD 0 | USD 41.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 151.44M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 179.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 78.02M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 56.17M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 61.36M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 98.18M | n/a | n/a | n/a |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tiziana Life Sciences Ltd's market cap?
Tiziana Life Sciences Ltd's market capitalization is USD 151.44M.
What does Tiziana Life Sciences Ltd do?
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.